secwatch.observer — SEC 8-K summary
======================================

Issuer:     Acurx Pharmaceuticals, Inc. (ACXP)
CIK:        0001736243
Form:       8-K
Filed at:   2025-02-26T23:59:59+00:00
Accession:  0001104659-25-017437
Event type: regulatory
Sentiment:  negative
Materiality: 0.60
Item codes: 3.01
LLM model:  deepseek-v4-flash:cloud@v2

Acurx Pharmaceuticals receives Nasdaq minimum bid price deficiency notice; 180-day cure period
--------------------------------------------------------------------------------

- Stock closed below $1.00 for 31 consecutive business days, triggering Nasdaq Listing Rule 5550(a)(2) deficiency.
- Company has until August 25, 2025 to regain compliance by closing at $1.00 or higher for 10 consecutive business days.
- If compliance not met, Company may seek a second 180-day period via a reverse stock split if other listing standards are met.
- No immediate effect on listing; stock continues trading on Nasdaq Capital Market under symbol 'ACXP'.
- Company intends to monitor bid price and consider available options but can provide no assurance of regaining compliance.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1736243/000110465925017437/0001104659-25-017437-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1736243/000110465925017437/tm257571d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-25-017437

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer